{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:54:54Z","timestamp":1781513694205,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004417","name":"The Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05159-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:25:21Z","timestamp":1773123921000},"page":"12343-12348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A combined statistical analysis based on the active pharmacovigilance and disproportionality assessment\u00a0for the safety of fluoroquinolones in shorter treatment of rifampicin-resistant tuberculosis"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-3096","authenticated-orcid":false,"given":"Hakob","family":"Atshemyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"5159_CR1","unstructured":"Hewison C, Khachatryan N, Bastard M, Hayrapetyan A, Yegiazaryan L, Atshemyan H et al (2018) From compassionate use to programmatic use of delamanid and bedaquiline: safety data from Armenia. IJTLD, Abstract Book. S421\u2013422"},{"key":"5159_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00228-7","author":"O Korotych","year":"2024","unstructured":"Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A et al (2024) Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(24)00228-7","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5159_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40265-018-1043-y","volume":"79","author":"AD Pranger","year":"2019","unstructured":"Pranger AD, van der TS, Kosterink JGW, Alffenaar JWC (2019) The role of fluoroquinolones in the treatment of tuberculosis. Drugs 79(2):161\u2013171. https:\/\/doi.org\/10.1007\/s40265-018-1043-y","journal-title":"Drugs"},{"key":"5159_CR4","doi-asserted-by":"crossref","unstructured":"Philipp du Cros, Khamraev A, Tigay Z, Abdrasuliev T, Greig J, Cooke G, et al. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan. ERJ Open Res. 2021;7(1):00537\u20132020.","DOI":"10.1183\/23120541.00537-2020"},{"key":"5159_CR5","unstructured":"Potter JL, Capstick T, Rickets WMR, Whitehead N, Kon OM (2024) A UK based resource to support the monitoring and safe use of anti-tuberculosis drugs and second line treatment of multidrug resistant tuberculosis. p 30.\u00a0https:\/\/www.tbdrugmonographs.co.uk\/levofloxacin.html"},{"key":"5159_CR6","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1164\/rccm.201308-1446ED","volume":"188","author":"NW Schluger","year":"2013","unstructured":"Schluger NW (2013) Fluoroquinolones in the treatment of tuberculosis: which is best? Am J Respir Crit Care Med 188:768\u2013769","journal-title":"Am J Respir Crit Care Med"},{"key":"5159_CR7","unstructured":"State and City TB Report\u00a0(2021) Data & Statistics\/ TB\/CDC. https:\/\/www.cdc.gov\/tb\/statistics\/indicators\/2021\/sputum-culture-conversion.htm#print1\/1 Esp"},{"key":"5159_CR8","unstructured":"The use of the World Health Organization-Uppsala Monitoring Center system for standardized case causality assessment (Publications, 1\u20133). Geneva, Switzerland: WHO. 2013"},{"key":"5159_CR9","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment (2019) Annex 2: dosage by weight band for medicines used in MDR-TB regimens, adults and children"},{"key":"5159_CR10","unstructured":"WHO consolidated guidelines on tuberculosis (2022) Module 4: treatment - drug-resistant tuberculosis treatment. Update; pp. 4\u20136, 11, 33, 46, 49, 55"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05159-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:18:39Z","timestamp":1781511519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05159-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5159"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05159-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the research meets the ethical guidelines, including adherence to the principles of the 2018 Declaration of Helsinki and the legal requirements of Armenia.The study was approved by the \u201cWHO Research Ethics Review Committee\u201d (30-Jul-2020, ERC.0003410), and local ethics review committee named \u201cHealthcare Research and Development Initiative ofArmenia\u201d (05-May-2020, HRDI-ERC-2020\u2013003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Every study participant provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}